Confo Therapeutics is developing CFTX-1554, a non-opioid treatment for neuropathic pain. It targets the angiotensin II type 2 receptor (AT2R), addressing prior challenges of off-target toxicity in pain management.

Jun 15, 2023 · Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G-protein coupled receptors), thereby enabling the discovery of chemical or biological ligands that are conformationally selective.

For decades, some of these receptors have eluded scientific advancement. With the advent of Confo’s technology, the landscape is transforming. We are now at the forefront of identifying and developing novel small molecules and antibodies for certain GPCRs once deemed intractable.

Mar 30, 2023 · Daiichi Sankyo has an exclusive option to acquire a worldwide exclusive license for the resulting compounds and advance them towards clinical development and commercialization. Confo has the potential to receive upfront payments, development and commercial milestones totaling EUR 168M and royalties.

Jun 28, 2022 · Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.

Oct 15, 2020 · Confo has applied its proprietary, fragment-based drug discovery and structure-guided drug design technologies to identify CFTX-1554, a novel inhibitor of angiotensin II type 2 receptor, or AT2R, a clinically validated target for the treatment of neuropathic pain.

Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant ...

Mar 10, 2022 · CFTX-1554 is Confo Therapeutics’ first product candidate in clinical development and is a non-opioid approach designed to address peripheral neuropathic pain while avoiding centrally mediated side effects, such as addiction and sedation.

Feb 2, 2016 · CONFO® technology allows medically relevant GPCRs to be stabilized in their active signaling state, revealing new binding pockets accessible for drug discovery. The investment amount of €6.7 million will be used to further establish the company in agonist GPCR drug screening, expand the team and build a portfolio of first in class pre ...

Mar 30, 2021 · Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.